Is Mersana Therapeutics Inc (NASDAQ:MRSN) a Buy? The Stock Reported more Sellers

The stock of Mersana Therapeutics Inc (NASDAQ:MRSN) registered an increase of 6.04% in short interest. MRSN’s total short interest was 625,100 shares in March as published by FINRA. Its up 6.04% from 589,500 shares, reported previously. With 90,200 shares average volume, it will take short sellers 7 days to cover their MRSN’s short positions. The short interest to Mersana Therapeutics Inc’s float is 6.43%.

The stock decreased 1.83% or $0.1 during the last trading session, reaching $5.36. About 188,994 shares traded. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has declined 74.65% since March 17, 2018 and is downtrending. It has underperformed by 79.02% the S&P500.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $255.59 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: which released: “Mid-Day Update: US Stocks Surrender Gains on Downbeat US Manufacturing Data – Nasdaq” on March 01, 2019, also with their article: “56 Biggest Movers From Yesterday – Benzinga” published on March 13, 2019, published: “64 Stocks Moving In Friday’s Mid-Day Session – Benzinga” on March 01, 2019. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: and their article: “Mersana Gets Clinical Hold Lifted, But Is Not Met With Welcomed Arms – Seeking Alpha” published on September 21, 2018 as well as‘s news article titled: “Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522 – GlobeNewswire” with publication date: September 17, 2018.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.